Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Pimecrolimus, tacrolimus keep in check pediatric AD
New Orleans - New long-term data with the topical immunomodulator tacrolimus(Protopic) and the skin-selective inflammatory cytokine inhibitor pimecrolimus(Elidel) demonstrate efficacy as maintenance therapies in the treatmentof atopic dermatitis in children. Data with pimecrolimus show safety andefficacy for as long as 26 weeks in infants as young as three months, LawrenceEichenfield, M.D., said at the annual meeting of the American Academy ofDermatology.
Related Videos
